Preserving hearing is our mission
Oricula Therapeutics, LLC, is working to develop the first medication approved to prevent hearing loss. Our first product will prevent the hearing loss that is a frequent side effect of the administration of an important class of antibiotics, the aminoglycosides. Reducing or eliminating hearing loss as a side effect of aminoglycoside therapy would allow broader worldwide use of these important antibiotics for the treatment of life-threatening bacterial infections, such as pneumonia, endocarditis, neonatal septicemia and multi-drug resistant tuberculosis. The FDA has allowed our Investigational New Drug (IND) filing for this product to move forward to early human testing.